Keith Tucker, FRCS, Chairman of the Orthopaedic Data Evaluation Panel (ODEP) and the Beyond Compliance Advisory Group, discusses the monitoring of orthopaedic implant performance.
Orthopaedics in the UK did not set out to build a global model for device evaluation. It was forced into it.
The National Joint Registry (NJR), the Orthopaedic Data Evaluation Panel (ODEP) and, later, Beyond Compliance were all born out of failure. In 2001, the 3M Capital hip and metal-on-metal implants exposed a fundamental weakness in how devices were assessed once they reached patients. We lacked real-time insight, could not identify affected patients and were slow to act.
That experience shaped everything that followed.
Today, the UK has developed a system that many healthcare systems are still trying to achieve; continuous monitoring of implant performance using real-world data, combined with independent clinical judgement. Increasingly, it is referenced beyond the UK as a practical model for post-market surveillance.
The question now is whether this model can, or should, extend further.
From registry to real-world assurance
The foundation of the UK approach is a broad evidence base in which the NJR plays a central role. ODEP accepts registry data, published studies and high-quality in-house evidence aligned to ISO 14155:2020 standards, though registry data remains the most robust due to its scale.
ODEP provides a structured framework for interpreting that evidence. Manufacturers submit data at defined intervals, progressing through benchmarks over time and demonstrating continued performance. If evidence is not submitted, ratings may lapse; if performance falls short, ratings are not awarded or are lost.
The system is not a simple pass or fail. Devices receive A or B ratings based on evidence quality. An A rating confirms sufficient high-quality data meets performance benchmarks, while A* denotes a higher standard, typically supported by multiple registries. Devices that fail to meet standards may be classified as “Unacceptable”, while “Withdrawn” or “Lapsed” reflect lack of support or evidence.
This is not purely statistical. Independent clinicians review the data, challenge assumptions and apply context. That combination of registry data and expert judgement underpins the system’s credibility and is reinforced through initiatives such as ODEP Assure, which emphasise continuous evaluation.
This approach has changed behaviour. Manufacturers must understand their data. Surgeons expect to see ODEP ratings before adopting implants, and patients increasingly ask about them. Over time, this has contributed to improved outcomes, with revision rates falling.
Closing the gap after approval
ODEP alone was not enough. The metal-on-metal experience showed that risk is often greatest in the early phase after market entry.
Beyond Compliance was created to address that gap. It provides structured monitoring between approval and the point at which sufficient data exists for an ODEP rating. Devices are assessed, risk evaluated and tracked through NJR data using consistent digital workflows.
Every use of a Beyond Compliance device is captured and reviewed, with surgeon feedback helping to identify early safety signals. This has led to design changes and improvements in clinical practice before wider rollout.
Importantly, this has not slowed innovation. Participation is voluntary and does not delay market entry. Instead, it provides confidence — supporting adoption by surgeons, hospitals and patients.
Why orthopaedics has succeeded
Orthopaedics has built what other device sectors are still trying to establish: a real-world, lifecycle evaluation system.
This is not just about scale. It reflects strong registry infrastructure, clinical leadership and a shared expectation that data should inform decision-making.
While often associated with hips and knees, ODEP has expanded to areas such as shoulders and spine, strengthening its relevance as a broader benchmarking framework. Without these elements, the model would not function.
The role of data infrastructure
Behind this system sits the infrastructure that enables data collection, linkage and analysis at scale. The NJR and Beyond Compliance rely on a national platform that captures procedures, records implants and tracks outcomes over time.
This capability has been developed with partners such as NEC Software Solutions, whose platforms enable these processes to function reliably at scale and turn data into actionable insight.
As discussions around expansion continue, this becomes critical. Scaling the model internationally will depend not only on clinical engagement, but on the ability to replicate this level of data quality and integration — an area where experienced delivery partners, such as NEC Software Solutions, are essential.
Can it be scaled?
There are already signs of international interest. ODEP ratings are referenced in procurement decisions outside the UK, and data from other registries is now used in certain benchmarks. Collaboration with countries such as the Netherlands is opening the door to wider integration, with international clinicians embedded within the ODEP panel structure.
However, scaling is not straightforward. It requires reliable registry data, independent clinical leadership and a culture that values transparency and continuous evaluation.
Crucially, evaluation must also be linked to procurement. In both the UK and the Netherlands, ODEP ratings inform purchasing decisions, often with minimum thresholds required. This ensures that evidence has direct market consequence.
Without these foundations, the model simply cannot be replicated.
A model worth protecting
The UK experience shows that effective post-market surveillance is achievable. It requires commitment to systematic data collection, independence and collaboration.
The model is already influencing thinking beyond the UK and has the potential to become a global benchmark for device evaluation. But its strength lies in the principles on which it was built. If those are diluted, its value will be quickly lost.
